Dominic Schmid

Dominic Schmid

Auto-generated profile, based on publicly available information

Dominic Schmid

Laboratory of Cancer Immunology, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MTMarcel P. Trefny
Marcel P. Trefny
NKNicole Kirchhammer
Nicole Kirchhammer
PMPriska Auf der Maur
Priska Auf der Maur
MNMarina Natoli
Marina Natoli
DSDominic Schmid
Dominic Schmid
AZAlfred Zippelius
Alfred Zippelius
Tumor-specific T cells are frequently exhausted by chronic antigenic stimulation. We here report on a human antigen-specific ex vivo model to explore new therapeutic options for T cell immunotherapies. T cells generated with this model resemble tumor-infiltrating exhausted T cells on a phenotypic and transcriptional level. Using a targeted pooled CRISPR-Cas9 screen and individual gene knockout validation experiments, we uncover sorting nexin-9 (SNX9) as a mediator of T cell exhaustion. Upon TCR/CD28 stimulation, deletion of SNX9 in CD8 T cells decreases PLCγ1, Ca2+, and NFATc2-mediated T cell signaling and reduces expression of NR4A1/3 and TOX. SNX9 knockout enhances memory differentiation and IFNγ secretion of adoptively transferred T cells and results in improved anti-tumor efficacy of human chimeric antigen receptor T cells in vivo. Our findings highlight that targeting SNX9 is a strategy to prevent T cell exhaustion and enhance anti-tumor immunity.

16 September 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
MRMiro E. Raeber
Miro E. Raeber
RRRodney A. Rosalia
Rodney A. Rosalia
DSDominic Schmid
Dominic Schmid
UKUfuk Karakus
Ufuk Karakus
OBOnur Boyman
Onur Boyman
IL-2 immunotherapy expands tumor-infiltrating DCs through a lymphoid pathway, favoring the conversion of poorly immunogenic into immunogenic tumors.

18 March 2021 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
DSDominic Schmid
Dominic Schmid
UWUwe Warnken
Uwe Warnken
PLPauline Latzer
Pauline Latzer
DHDirk C. Hoffmann
Dirk C. Hoffmann
JRJudith Roth
Judith Roth
TKTobias Kessler
Tobias Kessler
Recent technological advances in molecular diagnostics through liquid biopsies hold the promise to repetitively monitor tumor evolution and treatment response of brain malignancies without the need of invasive surgical tissue accrual. Here, we implemented a mass spectrometry‐based protein analysis pipeline which identified hundreds of proteins in 251 cerebrospinal fluid (CSF) samples from patients with four types of brain malignancies (glioblastoma, lymphoma, brain metastasis, and leptomeningeal disease [LMD]) and from healthy individuals with a focus on glioblastoma in a retrospective and confirmatory prospective observational study. CSF proteome deregulation via disruption of the blood brain barrier appeared to be largely conserved across brain tumor entities. CSF analysis of glioblastoma patients identified two proteomic clusters that correlated with tumor size and patient survival. By integrating CSF data with proteomic analyses of matching glioblastoma tumor tissue and primary glioblastoma cells, we identified potential CSF biomarkers for glioblastoma, in particular chitinase‐3‐like protein 1 (CHI3L1) and glial fibrillary acidic protein (GFAP). Key findings were validated in a prospective cohort consisting of 35 glioma patients. Finally, in LMD patients who frequently undergo repeated CSF work‐up, we explored our proteomic pipeline as a mean to profile consecutive CSF samples. Therefore, proteomic analysis of CSF in brain malignancies has the potential to reveal biomarkers for diagnosis and therapy monitoring. image

30 September 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DSDominic Schmid
Dominic Schmid
BSBettina Sobottka
Bettina Sobottka
MMMassimiliano Manzo
Massimiliano Manzo
MTMarta Trüb
Marta Trüb
KLKatharina Leonards
Katharina Leonards
AZAlfred Zippelius
Alfred Zippelius
Neoadjuvant chemoimmunotherapy offers promise to improve outcomes for patients with resectable non-small cell lung cancer (NSCLC). Yet not all patients derive treatment benefits, and reliable biomarkers of response are still lacking. We here assess the long-term clinical outcome of neoadjuvant chemotherapy and perioperative anti-PD-L1 inhibition in resectable stage IIIA NSCLC in the SAKK 16/14 trial and provide a comprehensive characterization of anti-tumor immune responses for biomarker-based treatment personalization. We report secondary outcomes of median event-free survival (EFS) of 4.0 years and median overall survival not being reached after a median follow-up of 5.4 years. Computer-aided spatial image analysis emphasizes the importance of CD8+ T cell positioning in tumors, and larger tertiary lymphoid structures in pre-treatment biopsies correlate with improved EFS. Genomic techniques reveal the association of intratumoral TCR diversity with response. Finally, circulating proliferating CD39+ PD-1+ CD8+ T cells and elevated levels of CCL15 post-treatment are seen in patients with sustained therapeutic benefit. NCT02572843.

19 October 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DSDominic Schmid
Dominic Schmid
PMPriska Auf der Maur
Priska Auf der Maur
MTMarcel P. Trefny
Marcel P. Trefny
AZAlfred Zippelius
Alfred Zippelius
T-cell exhaustion poses a significant barrier to the efficacy of immunotherapies. In the past decade, immune checkpoint blockade (ICB) has been the leading strategy to prevent or reverse T-cell exhaustion. Although ICB yields promising clinical outcomes in patients with cancer, its impact on T-cell reinvigoration is often short-lived. High-throughput genomic tools, including CRISPR screening along with single-cell RNA and chromatin accessibility sequencing may point toward new therapeutic avenues. However, their utility in identifying key mediators of T-cell exhaustion is constrained by the restricted scalability of well-validated in vivo exhaustion models, like chronic LCMV infection. In a recent article in Science Immunology, Wu and colleagues introduce an in vitro exhaustion model that involves repetitive stimulation of T-cell receptor-transgenic, LCMV-specific P14 CD8 T cells. This approach enables a direct comparison of exhausted T (Tex) cells generated both in vivo and in vitro using the same antigen, adeptly pinpointing exhaustion features that can be recapitulated in vitro. Leveraging this efficient and scalable model alongside CRISPR screening, the authors highlight the transcription factor BHLHE40 as a pivotal element in promoting Tex-cell transition from progenitor to intermediate Tex cells.

19 April 2024 in Research Square
Verified
Preprint
Open access
PDF file
DSDominic Schmid
Dominic Schmid
ASAnna Bettina Sobottka-Brillout
Anna Bettina Sobottka-Brillout
MMMassimiliano Manzo
Massimiliano Manzo
MTMarta Trüb
Marta Trüb
KLKatharina Leonards
Katharina Leonards
AZAlfred Zippelius
Alfred Zippelius
Neoadjuvant chemoimmunotherapy offers promise to improve outcomes for patients with resectable non-small cell lung cancer (NSCLC). Yet, not all patients derive treatment benefits and reliable biomarkers of response are still lacking. We here assess the long-term clinical outcome of neoadjuvant chemotherapy and perioperative anti-PD-L1 inhibition in resectable stage IIIA NSCLC in the SAKK 16/14 trial and provide a comprehensive characterization of anti-tumor immune responses for biomarker-based treatment personalization. At a median follow-up of 5.3 years, the median event-free survival (EFS) was 4.0 years while median overall survival was not reached. Computer-aided spatial image analysis emphasized the importance of CD8+ T cell positioning in tumors, and larger tertiary lymphoid structures in pre-treatment biopsies correlated with improved EFS. Genomic techniques revealed the association of intratumoral TCR diversity with response. Finally, circulating proliferating CD39+ PD-1+ CD8+ T cells and elevated levels of CCL15 post-treatment were seen in patients with sustained therapeutic benefit.